Impact of Partnership with Carevive

Carrie Wines-Larch, a nurse navigator and survivorship coordinator, shares the challenges faced in the infusion clinic at the Cancer Center at Charleston Area Medical Center. Patients arriving unprepared for treatment due to scheduling difficulties and delayed referrals prompted the need for a solution. The implementation of Carevive’s clinic allowed for a pre-infusion check to ensure services were completed or scheduled. This streamlined the process, benefiting both the department and the community. Lori Russell, another nurse navigator, highlights the significance of Carevive in tracking patient symptoms and enabling timely communication for effective care. Kara Smith, a breast nurse navigator, shares her positive experience with the Carevive app. The weekly check-ins provided her with valuable support, while patients felt more connected and cared for. Overall, Carevive’s platform has improved cancer care, fostering better communication, and facilitating efficient workflows.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…